Novo Nordisk (NVO) Market Cap (1999 - 2026)
Novo Nordisk (NVO) market cap from Nov 1, 1999 to Jul 21, 2026. The current Novo Nordisk (NVO) market cap is $220B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Market Cap
Novo Nordisk (NVO) Market Cap CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -48.02% |
| 3 Years TTM | -10.57% |
| 5 Years TTM | +5.26% |
| 10 Years TTM | +4.36% |
| All Time TTM | +14.11% |
Annual Market Cap change of Novo Nordisk (NVO)
| Year | Market Cap | Change |
|---|---|---|
| 2026 | $220B | -2.93% |
| 2025 | $226B | -41.02% |
| 2024 | $384B | -17.38% |
| 2023 | $464B | +51.26% |
| 2022 | $307B | +19.55% |
| 2021 | $257B | +57.94% |
| 2020 | $163B | +18.70% |
| 2019 | $137B | +22.78% |
| 2018 | $112B | -15.81% |
| 2017 | $133B | +46.03% |
| 2016 | $91B | -39.32% |
| 2015 | $150B | +34.58% |
| 2014 | $111B | +12.50% |
| 2013 | $99B | +10.86% |
| 2012 | $89B | +36.09% |
| 2011 | $65B | +0.10% |
| 2010 | $65B | +71.14% |
| 2009 | $38B | +19.84% |
| 2008 | $32B | -22.69% |
| 2007 | $41B | +53.28% |
| 2006 | $27B | +114.98% |
| 2005 | $13B | +3.72% |
| 2004 | $12B | +32.47% |
| 2003 | $9.11B | +41.73% |
| 2002 | $6.43B | -27.93% |
| 2001 | $8.92B | +13.28% |
| 2000 | $7.87B | +36.93% |
| 1999 | $5.75B | N/A |
Comparison Novo Nordisk (NVO) market cap with competitors
Novo Nordisk (NVO) market cap is $219.68B.
| Ticker | Name | Market Cap | Upside |
|---|---|---|---|
| LLY | Lilly(Eli) & Company | $1.03T | +370.79% |
| JNJ | Johnson & Johnson | $594.97B | +170.84% |
| ABBV | Abbvie Inc | $432.22B | +96.75% |
| AZN | Astrazeneca plc | $295.54B | +34.54% |
| MRK | Merck & Co Inc | $291.57B | +32.73% |
| AMGN | AMGEN Inc | $193.39B | -11.97% |
| GILD | Gilead Sciences Inc | $163.57B | -25.54% |
| PFE | Pfizer Inc | $141.25B | -35.70% |
| BMY | Bristol-Myers Squibb Company | $119.63B | -45.54% |
| SNY | Sanofi | $105.20B | -52.11% |
| GSK | GSK Plc | $104.78B | -52.30% |
| BIIB | Biogen Inc | $29.03B | -86.78% |
| GRFS | Grifols SA | $4.91B | -97.77% |
| OGN | Organon & Company | $3.54B | -98.39% |
| AMRN | Amarin Corp | $303.37M | -99.86% |
| SCLX | Scilex Holding Company | $78.29M | -99.96% |
| MIRA | Mira Pharmaceuticals Inc | $39.50M | -99.98% |
| NSRX | Nasus Pharma Ltd | $28.10M | -99.99% |
| MDCXW | Medicus Pharma Ltd warrant | $19.20M | -99.99% |
| MDCX | MDCorp | $13.93M | -99.99% |